



Diabetes UK Professional Conference 2024

April 17-19, 2024; London, UK; Resource Hub – Draft

Welcome to our resource hub for Diabetes UK Professional Conference 2024! This is a one-stop-shop for all your DUK 2024 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Diabetes Big Picture Highlights](#)

[Exhibit Hall](#)

[Previous Diabetes UK Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [Diabetes UK 2024 Day #1 Highlights](#)
2. [Diabetes UK 2024 Day #2 Highlights](#)
3. [Diabetes UK 2024 Day #3 Highlights](#)

Diabetes Therapy Highlights

1. [England audit highlights concerning underuse of urine albumin-creatinine ratio testing for early diagnosis of diabetic kidney disease](#)
2. [Pharmacotherapy for kidney disease: Prof. Kamlesh Khunti discusses efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists across broad patient population](#)
3. [Prof. Tim Barrett discusses T1D Plus trials platform investigating verapamil in combination with Tzield and other immunotherapies](#)
4. [“Type 1 diabetes is not a single disease”: Prof. Noel Morgan presents new data supporting the existence of endotypes](#)
5. [Quick Take: Updates on current and emerging diabetes and obesity therapies from a UK lens](#)
6. [Targeting unifying drivers of MASLD: Oxford’s Dr. Thomas Marjot encourages HCPs to focus on encouraging weight and glycemic control](#)
7. [The endothelial glycocalyx may be the missing link between albuminuria and systemic vascular disease in microvascular complications of diabetes](#)

8. [Professor Angus Jones explains that diagnosis of type 1 diabetes in adults is like a “needle in a haystack” in RD Lawrence Lecture](#)
9. [Professor Naveed Sattar discusses the interplay of cardio-renal-metabolic disease in type 1 diabetes and type 2 diabetes](#)

Diabetes Technology Highlights

1. [Prof. Roman Hovorka delivers exceptional Banting Memorial Lecture on AID](#)
2. [Small study on AID in pregnancy in T1D \(n=36\) finds +8.2 hour/day increase in pregnancy TIR and 1.7% reduction in A1c across four commercial systems](#)
3. [Poster hall highlights early UK Omnipod 5 data demonstrating impressive TIR increases and low hypo](#)
4. [“The system puts all the pieces together”: Ms. Amy Jolley highlights Medtronic’s Smart MDI system, discussing candidates, funding, and new features](#)
5. [Ms. Kathryn Fraser does a deep dive into the Control-IQ algorithm](#)
6. [University of Nottingham’s Dr. Pooja Sachdev and Ms. Ressa Cresswell review ins and outs of algorithm setting adjustments for children on AID](#)
7. [Trial outcomes from T1D pregnancies \(n=2,055\) following CGM rollout: Prof. Helen Murphy shares insightful results](#)
8. [Prof. Alice Cheng on the future of insulin, technology, and digital health](#)

Diabetes Big Picture Highlights

1. [Shaping the future of diabetes care: Prof. Melanie Davies on innovation, people, interventions, and partnerships](#)
2. [Genetic variant in South Asian people may lead to underestimation of A1c levels and delayed diabetes diagnosis, genome-wide association study finds](#)
3. [University of Edinburgh’s Prof. Sarah Wild on the changing patterns of diabetes in the 21st century](#)
4. [Workshop spotlights cardio-renal-metabolic disease, with a focus on primary care and community-based solutions](#)
5. [National UK consensus on management of T2D in children and young people](#)
6. [Harry Keen Rank Nutrition Lecture: Dr. John Wilding on weight loss as primary goal in T2D treatment and prevention](#)
7. [Professor Roy Taylor discusses how the new understanding of T2D informs roll out of remission services](#)
8. [Quick Take: Screening for diabetic retinopathy is evolving as barriers remain](#)
9. [Quick Take: National Diabetes Audit as a source for quality indicators that can influence coverage for tech and therapies](#)
10. [Quick Take: In the exhibit hall, we saw Abbott, AstraZeneca, Dexcom, Lilly, Novo Nordisk, and more](#)
11. [Papers to People: Profs. Partha Kar and Helen Murphy on implementing policy change with PWDs](#)
12. [Prof. Kath Barnard Kelly, Dr. Vicky McKechnie, Prof. Pratik Choudhary and Dr. Nicole de Zoysa on the biopsychosocial impact of tech and hyperglycemia aversion](#)

Exhibit Hall

Therapy

1. [AstraZeneca](#)
2. [Lilly](#)
3. [Lilly/BI](#)

4. [Madrigal](#)
5. [Menarini Farmaceutica](#)
6. [Sanofi](#)

Technology

1. [Abbott](#)
2. [Dexcom](#)
3. [embecta](#)
4. [Glooko](#)
5. [Insulet](#)
6. [Medtronic](#)
7. [Medtrum](#)
8. [Ypsomed](#)

Big Picture

1. [JDRF UK](#)
2. [Diabetes UK](#)
3. [NHS England](#)

Previous Diabetes UK Coverage on CCKB

1. [Diabetes UK 2023 Resource Hub](#)
2. [Diabetes UK 2022 Resource Hub](#)
3. [Diabetes UK 2021 Full Report](#)
4. [Diabetes UK 2019 Full Report](#)
5. [Diabetes UK 2018 Full Report](#)
6. [Diabetes UK 2017 Full Report](#)
7. [Diabetes UK 2016 Full Report](#)